Clinical Trials List
Protocol NumberCINC280L12301
Completed
2022-03-01 - 2022-05-18
Phase III
Terminated2
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 徐偉勛 Division of Hematology & Oncology
- 陳冠宇 Division of Hematology & Oncology
- 蔡子修 Division of Hematology & Oncology
- YEN-TING LIN Division of Hematology & Oncology
- Chia-Chi Lin Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- CHAO-CHI HO CHAO-CHI HO Division of Hematology & Oncology
- 楊景堯 Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- JIN-YUAN SHIH Division of Hematology & Oncology
- 許嘉林 Division of Hematology & Oncology
- Jih-Hsiang Lee Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- Chong-Jen Yu Division of Hematology & Oncology
- 廖唯昱 Division of Hematology & Oncology
- 吳尚俊 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10 participants
-
Global
255 participants
